Multiple Myeloma
Oncology 18 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q3 2027
Equecabtagene Autoleucel Injection
Nanjing IASO Biotechnology Co., Ltd.
Estimated · aging NCT06464991
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 130 industry trials with a known mechanism of action.
BCMA/CD3
10 trials 8 active 2 sponsors
CD38-directed Cytolytic Antibody
19 trials 5 active 5 sponsors
Nuclear Export Inhibitor
8 trials 4 active 3 sponsors
Proteasome Inhibitor
26 trials 2 active 10 sponsors
Thalidomide Analog
25 trials 2 active 5 sponsors
Corticosteroid
9 trials 2 active 6 sponsors
BCL-2 Inhibitor
7 trials 2 active 2 sponsors
SLAMF7-directed Immunostimulatory Antibody
8 trials 2 sponsors
Programmed Death Receptor-1 Blocking Antibody
7 trials 2 sponsors
Histone Deacetylase Inhibitor
4 trials 1 sponsor
Kinase Inhibitor
4 trials 3 sponsors
DNA
3 trials 3 sponsors
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
713 industry-sponsored trials across 235 sponsors
Showing 11 of 11 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Johnson & Johnson Private Limited | Teclistamab | — | RECRUITING | 2026-11-03 | NCT07030517 |
| Pfizer | Elranatamab | BCMA/CD3 | RECRUITING | 2032-02-22 | NCT06057402 |
| Johnson & Johnson | Cilta-cel | — | RECRUITING | 2037-07-29 | NCT05201781 |
| Amgen | Drug: Carfilzomib + Dexamethasone | — | COMPLETED | 2023-03-23 | NCT03934684 |
| Johnson & Johnson Private Limited | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | COMPLETED | 2022-07-16 | NCT03768960 |
| CASI Pharmaceuticals (China) Co., Ltd. | Melphalan Hydrochloride for Injection | — | COMPLETED | 2021-07-08 | NCT06425276 |
| Takeda | Ixazomib | — | COMPLETED | 2021-05-28 | NCT03416374 |
| Johnson & Johnson Taiwan Ltd | Bortezomib | Proteasome Inhibitor [EPC] | COMPLETED | 2015-07 | NCT02268890 |
| Takeda | Ixazomib | — | TERMINATED | 2026-03-30 | NCT03173092 |
| Takeda | Ixazomib | — | WITHDRAWN | 2026-12-31 | NCT05183139 |
| DFINE Inc. | — | — | WITHDRAWN | — | NCT01410929 |
Showing 100 of 119 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Pfizer | Elranatamab | BCMA/CD3 | RECRUITING | 2026-08-30 | NCT06152575 |
| Guangzhou Gloria Biosciences Co., Ltd. | Motixafortide+G-CSF | — | RECRUITING | 2026-12-31 | NCT06514508 |
| Bristol-Myers Squibb | mezigdomide | — | RECRUITING | 2027-01-10 | NCT05519085 |
| Hangzhou Sumgen Biotech Co., Ltd. | SG301 Injection | — | RECRUITING | 2027-03-31 | NCT06508983 |
| Nanjing IASO Biotechnology Co., Ltd. | Equecabtagene Autoleucel Injection | — | RECRUITING | 2027-08 | NCT06464991 |
| Celltrion | CT-P44(Daratumumab) | — | RECRUITING | 2027-11-15 | NCT06952478 |
| AbbVie | Etentamig | — | RECRUITING | 2027-12 | NCT06158841 |
| Qilu Pharmaceutical Co., Ltd. | QLS32015 | — | RECRUITING | 2027-12 | NCT07138209 |
| Sinocelltech Ltd. | SCTC21C | — | RECRUITING | 2027-12 | NCT07297329 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | BMS-986393 | — | RECRUITING | 2027-12-30 | NCT06615479 |
| AstraZeneca | AZD0120 | — | RECRUITING | 2028-06-14 | NCT07391657 |
| Kite, A Gilead Company | Anitocabtagene Autoleucel | — | RECRUITING | 2028-07 | NCT06413498 |
| Grifols Biologicals, LLC | Gamunex-C, 10% Injectable Solution | — | RECRUITING | 2028-08-31 | NCT07582432 |
| Takeda | IGI, 10% | — | RECRUITING | 2028-09-11 | NCT06980480 |
| Johnson & Johnson | JNJ-79635322 | — | RECRUITING | 2028-12-12 | NCT07258511 |
| Shandong New Time Pharmaceutical Co., LTD | F182112 single-agent | — | RECRUITING | 2029-01-25 | NCT07579234 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | RECRUITING | 2029-01-31 | NCT05438043 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injection | — | RECRUITING | 2029-03 | NCT07452198 |
| Bristol-Myers Squibb | Iberdomide | — | RECRUITING | 2029-03-15 | NCT05827016 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2029-06-15 | NCT07222761 |
| Pfizer | Elranatamab | BCMA/CD3 | RECRUITING | 2030-10-18 | NCT05623020 |
| GSK | Belantamab mafodotin | — | RECRUITING | 2031-04-28 | NCT06679101 |
| Johnson & Johnson | Teclistamab | — | RECRUITING | 2031-04-30 | NCT05552222 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2033-04-19 | NCT05730036 |
| AbbVie | Etentamig | — | RECRUITING | 2042-01 | NCT07095452 |
| Pfizer | Elranatamab | BCMA/CD3 | RECRUITING | 2026-04-27 | NCT05020236 |
| Johnson & Johnson | Talquetamab | — | RECRUITING | 2026-04-23 | NCT06208150 |
| Biocad | BCD-264 | — | RECRUITING | 2025-01 | NCT06296121 |
| Bristol-Myers Squibb | Mezigdomide | — | ACTIVE NOT RECRUITING | 2026-07-18 | NCT05552976 |
| AbbVie | Pomalidomide | Thalidomide Analog [EPC] | ACTIVE NOT RECRUITING | 2026-08 | NCT03539744 |
| Bristol-Myers Squibb | bb2121 | — | ACTIVE NOT RECRUITING | 2027-04-08 | NCT03651128 |
| Johnson & Johnson | Talquetamab | — | ACTIVE NOT RECRUITING | 2027-07-30 | NCT05455320 |
| AbbVie | Venetoclax | BCL-2 Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-08 | NCT03844048 |
| Pfizer | Elranatamab | BCMA/CD3 | ACTIVE NOT RECRUITING | 2027-08-04 | NCT05317416 |
| Bristol-Myers Squibb | Dexamethasone | Corticosteroid [EPC] | ACTIVE NOT RECRUITING | 2027-11-16 | NCT04975997 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | ACTIVE NOT RECRUITING | 2028-12-08 | NCT05083169 |
| Johnson & Johnson | Bortezomib | Proteasome Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2029-02-14 | NCT04923893 |
| Antengene Corporation | — | — | ACTIVE NOT RECRUITING | 2025-12-31 | NCT04939142 |
| Johnson & Johnson | Teclistamab | — | ACTIVE NOT RECRUITING | 2025-10-13 | NCT05572515 |
| Bristol-Myers Squibb | idecabtagene vicleucel | — | ACTIVE NOT RECRUITING | 2025-08-11 | NCT06045806 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2024-05-27 | NCT06956170 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | ACTIVE NOT RECRUITING | 2024-05-07 | NCT03652064 |
| Johnson & Johnson | Cilta-cel | — | ACTIVE NOT RECRUITING | 2024-05-01 | NCT04181827 |
| Johnson & Johnson | Daratumumab SC: daratumumab + rHuPH20 | — | ACTIVE NOT RECRUITING | 2024-05-01 | NCT03301220 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | ACTIVE NOT RECRUITING | 2024-04-04 | NCT03901963 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2024-04-03 | NCT06868654 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2024-04-03 | NCT06868667 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2024-01-29 | NCT04484623 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2023-10-02 | NCT04246047 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2022-09-12 | NCT04162210 |
| BioLineRx, Ltd. | BL-8040 1.25 mg/kg + G-CSF | — | ACTIVE NOT RECRUITING | 2020-12-22 | NCT03246529 |
| Shanghai Henlius Biotech | HLX15-IV | — | NOT YET RECRUITING | 2027-07 | NCT06895512 |
| Keymed Biosciences Co.Ltd | CM336 Injection | — | NOT YET RECRUITING | 2027-09 | NCT07181239 |
| Qilu Pharmaceutical Co., Ltd. | QL2109 | — | NOT YET RECRUITING | 2027-12 | NCT06742138 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQB2934 injection | — | NOT YET RECRUITING | 2028-12 | NCT07569757 |
| Johnson & Johnson | JNJ-79635322 | — | NOT YET RECRUITING | 2029-04-29 | NCT07518186 |
| Roche | Cevostamab | — | NOT YET RECRUITING | 2029-06-29 | NCT07555938 |
| Regeneron | Linvoseltamab | — | NOT YET RECRUITING | 2033-07-22 | NCT07393282 |
| Regeneron | Linvoseltamab | — | NOT YET RECRUITING | 2038-05-21 | NCT07428369 |
| TJ Biopharma Co., Ltd. | TJ202, Lenalidomide and Dexamethasone | — | COMPLETED | 2024-06-30 | NCT03952091 |
| Millennium Pharmaceuticals, Inc. | Ixazomib | — | COMPLETED | 2023-12-06 | NCT03748953 |
| Amgen | Carfilzomib | Proteasome Inhibitor [EPC] | COMPLETED | 2023-03-31 | NCT03859427 |
| Bristol-Myers Squibb | Pomalidomide | Thalidomide Analog [EPC] | COMPLETED | 2022-05-09 | NCT01734928 |
| Bristol-Myers Squibb | Nivolumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2022-03-09 | NCT02726581 |
| AbbVie | Venetoclax | BCL-2 Inhibitor [EPC] | COMPLETED | 2021-03-15 | NCT02755597 |
| Bristol-Myers Squibb | Lenalidomide | Thalidomide Analog [EPC] | COMPLETED | 2020-10-12 | NCT02112175 |
| Johnson & Johnson | Velcade | Proteasome Inhibitor [EPC] | COMPLETED | 2020-07-02 | NCT03217812 |
| Karyopharm Therapeutics Inc | Selinexor | Nuclear Export Inhibitor [EPC] | COMPLETED | 2020-02-18 | NCT03110562 |
| Bristol-Myers Squibb | Pomalidomide | Thalidomide Analog [EPC] | COMPLETED | 2019-12-11 | NCT01712789 |
| Millennium Pharmaceuticals, Inc. | Ixazomib | — | COMPLETED | 2019-12-02 | NCT01850524 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | COMPLETED | 2019-10-07 | NCT03234972 |
| Bristol-Myers Squibb | Lenalidomide | Thalidomide Analog [EPC] | COMPLETED | 2019-10-01 | NCT01335399 |
| Takeda | Ixazomib | — | COMPLETED | 2019-08-12 | NCT02312258 |
| Amgen | Dexamethasone | Corticosteroid [EPC] | COMPLETED | 2019-07-14 | NCT03158688 |
| Johnson & Johnson | Dara SC | — | COMPLETED | 2019-06-27 | NCT03277105 |
| Amgen | Dexamethasone | Corticosteroid [EPC] | COMPLETED | 2018-11-05 | NCT03029234 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | COMPLETED | 2018-10-24 | NCT03357952 |
| Johnson & Johnson | Daratumumab IV | — | COMPLETED | 2018-09-24 | NCT02252172 |
| Johnson & Johnson | Bortezomib | Proteasome Inhibitor [EPC] | COMPLETED | 2018-05-07 | NCT02811978 |
| Takeda | Ixazomib Citrate | Proteasome | COMPLETED | 2018-04-16 | NCT02181413 |
| Johnson & Johnson | Velcade | Proteasome Inhibitor [EPC] | COMPLETED | 2017-11-21 | NCT02195479 |
| PharmaMar | Plitidepsin | — | COMPLETED | 2017-11 | NCT01102426 |
| Amgen | Carfilzomib | Proteasome Inhibitor [EPC] | COMPLETED | 2017-06-15 | NCT02412878 |
| Amgen | Denosumab | RANK Ligand Inhibitor [EPC] | COMPLETED | 2016-07-19 | NCT01345019 |
| Amgen | Carfilzomib | Proteasome Inhibitor [EPC] | COMPLETED | 2016-07-15 | NCT01818752 |
| Bristol-Myers Squibb | Lenalidomide and low-dose dexamethasone | — | COMPLETED | 2016-07-14 | NCT00689936 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | COMPLETED | 2016-03-07 | NCT02076009 |
| Janssen-Cilag International NV | bortezomib (optimized retreatment) | — | COMPLETED | 2016-02 | NCT01910987 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | COMPLETED | 2016-01-11 | NCT02136134 |
| Janssen Scientific Affairs, LLC | Thalidomide | Cereblon | COMPLETED | 2015-12-30 | NCT01539083 |
| Novartis | Panobinostat | — | COMPLETED | 2015-07-30 | NCT01023308 |
| Amgen | Carfilzomib | Proteasome Inhibitor [EPC] | COMPLETED | 2014-11-10 | NCT01568866 |
| Takeda | Ixazomib | — | COMPLETED | 2014-10-01 | NCT01564537 |
| Bristol-Myers Squibb | Lenalidomide | Thalidomide Analog [EPC] | COMPLETED | 2014-09-02 | NCT01239797 |
| Bristol-Myers Squibb | pomalidomide | Thalidomide Analog [EPC] | COMPLETED | 2014-07-31 | NCT01324947 |
| Amgen | Carfilzomib | Proteasome Inhibitor [EPC] | COMPLETED | 2014-07 | NCT01302392 |
| Amgen | Dexamethasone | Corticosteroid [EPC] | COMPLETED | 2014-06-16 | NCT01080391 |
| Oncotherapeutics | armodafinil | DAT | COMPLETED | 2013-06 | NCT01160380 |
| Bristol-Myers Squibb | pomalidomide | Thalidomide Analog [EPC] | COMPLETED | 2013-03-01 | NCT01311687 |
| Janssen-Cilag G.m.b.H | Dexamethasone | Corticosteroid [EPC] | COMPLETED | 2013-01 | NCT00813150 |
Showing 100 of 300 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Starton Therapeutics, Inc | Lenalidomide | Thalidomide Analog [EPC] | RECRUITING | 2026-05-31 | NCT06087653 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injection | — | RECRUITING | 2026-08-01 | NCT06566547 |
| Bristol-Myers Squibb | CC-92480 | — | RECRUITING | 2026-10-12 | NCT05372354 |
| Nanjing Leads Biolabs Co.,Ltd | LBL-034 for Injection | — | RECRUITING | 2026-10-20 | NCT06049290 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI3003 | — | RECRUITING | 2026-10-31 | NCT06083207 |
| BeOne Medicines | Sonrotoclax | — | RECRUITING | 2026-11 | NCT04973605 |
| OriCell Therapeutics Co., Ltd. | OriCAR-017 | — | RECRUITING | 2026-11-30 | NCT06182696 |
| Keymed Biosciences Co.Ltd | CM336_group 1 | — | RECRUITING | 2026-12 | NCT05299424 |
| Zhejiang ACEA Pharmaceutical Co. Ltd. | STI-6129 | — | RECRUITING | 2026-12-31 | NCT05565807 |
| Chongqing Precision Biotech Co., Ltd | BCMA targeted prime CAR-T cells | — | RECRUITING | 2026-12-31 | NCT04776330 |
| Chongqing Precision Biotech Co., Ltd | BCMA CAR-T cells | — | RECRUITING | 2026-12-31 | NCT04271644 |
| Beijing Biotech | Autologous CD19/CD22 dual-target CAR-T module | — | RECRUITING | 2027-03-14 | NCT07523555 |
| CellCentric Ltd. | CCS1477 | — | RECRUITING | 2027-03-31 | NCT04068597 |
| Bristol-Myers Squibb | Elranatamab | BCMA/CD3 | RECRUITING | 2027-05-31 | NCT06988488 |
| Johnson & Johnson | JNJ-79635322 | — | RECRUITING | 2027-06-14 | NCT07266441 |
| Sumitomo Pharma America, Inc. | Enzomenib | — | RECRUITING | 2027-06-30 | NCT04988555 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Arlocabtagene Autoleucel | — | RECRUITING | 2027-06-30 | NCT06297226 |
| AstraZeneca | AZD0305 | — | RECRUITING | 2027-08-16 | NCT06106945 |
| AstraZeneca | AZD0120 | — | RECRUITING | 2027-08-31 | NCT05850234 |
| Qilu Pharmaceutical Co., Ltd. | QLS32015 | — | RECRUITING | 2027-11 | NCT07018050 |
| Karyopharm Therapeutics Inc | Selinexor | Nuclear Export Inhibitor [EPC] | RECRUITING | 2028-01 | NCT04414475 |
| Johnson & Johnson | Cilta-cel | — | RECRUITING | 2028-04-12 | NCT07149857 |
| Shandong New Time Pharmaceutical Co., LTD | F182112+P | — | RECRUITING | 2028-05-20 | NCT07312188 |
| Roche | Cevostamab | — | RECRUITING | 2028-07-31 | NCT05583617 |
| CellCentric Ltd. | Inobrodib | — | RECRUITING | 2029-12-01 | NCT07096778 |
| GSK | Unconjugated belantamab antibody | — | RECRUITING | 2029-12-03 | NCT05714839 |
| C4 Therapeutics, Inc. | Cemsidomide | — | RECRUITING | 2030-03 | NCT07284758 |
| Johnson & Johnson | Talquetamab | — | RECRUITING | 2030-05-30 | NCT06500884 |
| ModernaTX, Inc. | mRNA-2808 | — | RECRUITING | 2030-06-17 | NCT07116616 |
| GSK | Belantamab mafodotin | — | RECRUITING | 2030-08-30 | NCT07227311 |
| AbbVie | ABBV-453 | — | RECRUITING | 2030-12 | NCT06953960 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2032-05-18 | NCT06140524 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2033-03-30 | NCT03761108 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2033-09-30 | NCT07455851 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2033-11-11 | NCT06669247 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2035-11-02 | NCT05828511 |
| AbbVie | Etentamig | — | RECRUITING | 2036-02 | NCT06892522 |
| Oncotherapeutics | Venetoclax | BCL-2 Inhibitor [EPC] | RECRUITING | 2026-04-30 | NCT06115135 |
| Gracell Biotechnologies (Shanghai) Co., Ltd. | GC012F | — | RECRUITING | 2026-03-02 | NCT06235229 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | Purinostat Mesylate 4 mg/m2 | — | RECRUITING | 2026-02-01 | NCT06484829 |
| Biocad | BCD-248 | — | RECRUITING | 2026-02 | NCT06668792 |
| Beijing Mabworks Biotech Co., Ltd. | MBS314 Injection | — | RECRUITING | 2026-02 | NCT06232096 |
| DexTech Medical AB | ODX (Osteodex) | — | RECRUITING | 2026-01-30 | NCT06616389 |
| Indapta Therapeutics, INC. | IDP-023 | — | RECRUITING | 2025-12-30 | NCT06119685 |
| GI Cell, Inc. | GIC-102 | — | RECRUITING | 2025-12-30 | NCT05880043 |
| IDP Discovery Pharma S.L. | IDP-121 | — | RECRUITING | 2025-12-22 | NCT05908409 |
| Heidelberg Pharma AG | HDP-101 | — | RECRUITING | 2025-08 | NCT04879043 |
| Hrain Biotechnology Co., Ltd. | Human BCMA Targeted T Cells Injection | — | RECRUITING | 2025-07-31 | NCT05594797 |
| Shanghai AbelZeta Ltd. | B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell | — | RECRUITING | 2024-07 | NCT05521802 |
| US Oncology Research | Selinexor | Nuclear Export Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2026-05-31 | NCT04782687 |
| Cellectar Biosciences, Inc. | Iopofosine I 131 single dose | — | ACTIVE NOT RECRUITING | 2026-06-22 | NCT02952508 |
| Johnson & Johnson | JNJ-68284528 | — | ACTIVE NOT RECRUITING | 2026-08-04 | NCT04133636 |
| Johnson & Johnson | Cilta-cel | — | ACTIVE NOT RECRUITING | 2026-08-31 | NCT06550895 |
| Bristol-Myers Squibb | CC-92480 | — | ACTIVE NOT RECRUITING | 2026-11-30 | NCT03989414 |
| Kite, A Gilead Company | anitocabtagene-autoleucel | — | ACTIVE NOT RECRUITING | 2026-12 | NCT05396885 |
| Roche | Cevostamab | — | ACTIVE NOT RECRUITING | 2027-02-26 | NCT05535244 |
| Karyopharm Therapeutics Inc | Selinexor | Nuclear Export Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-04 | NCT02343042 |
| AbbVie | Carfilzomib | Proteasome Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-06 | NCT02899052 |
| Johnson & Johnson | Cilta-cel | — | ACTIVE NOT RECRUITING | 2030-09-02 | NCT06577025 |
| AbbVie | Dexamethasone | Corticosteroid [EPC] | ACTIVE NOT RECRUITING | 2031-05 | NCT03314181 |
| Regeneron | Linvoseltamab | — | ACTIVE NOT RECRUITING | 2033-01-25 | NCT05955508 |
| AbbVie | TNB-383B | — | ACTIVE NOT RECRUITING | 2026-05 | NCT03933735 |
| Sanofi | Isatuximab | — | ACTIVE NOT RECRUITING | 2025-12-22 | NCT05704049 |
| Sorrento Therapeutics, Inc. | STI-6129 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05308225 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT04126200 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT07084896 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT07217184 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT07217119 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT07150104 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-17 | NCT07150091 |
| Otsuka Pharmaceutical Co., Ltd. | OPC-415 | — | ACTIVE NOT RECRUITING | 2025-04-09 | NCT04649073 |
| Johnson & Johnson | Talquetamab | — | ACTIVE NOT RECRUITING | 2025-03-18 | NCT04586426 |
| CARsgen Therapeutics Co., Ltd. | zevor-cel | — | ACTIVE NOT RECRUITING | 2024-12-31 | NCT03915184 |
| MitoImmune Therapeutics | MIT-001 | — | ACTIVE NOT RECRUITING | 2024-06-30 | NCT05493800 |
| Bristol-Myers Squibb | CC-220 | — | ACTIVE NOT RECRUITING | 2024-05-09 | NCT02773030 |
| Pfizer | Elranatamab (PF-06863135) | — | ACTIVE NOT RECRUITING | 2022-06-17 | NCT04649359 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | SYHX1903 | — | NOT YET RECRUITING | 2026-06-20 | NCT05055791 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injection | — | NOT YET RECRUITING | 2026-07-31 | NCT07090954 |
| CARsgen Therapeutics Co., Ltd. | CT071 | — | NOT YET RECRUITING | 2027-06-15 | NCT06333509 |
| Hangzhou Sumgen Biotech Co., Ltd. | SG2918 | — | NOT YET RECRUITING | 2027-09-30 | NCT07454187 |
| Fortvita Biologics (USA)Inc. | IBI3003 | — | NOT YET RECRUITING | 2027-12-31 | NCT07336472 |
| Johnson & Johnson | Ramantamig | — | NOT YET RECRUITING | 2027-12-31 | NCT07589634 |
| Biotroy Therapeutics | BT02 | — | NOT YET RECRUITING | 2028-01 | NCT07107204 |
| Hebei Senlang Biotechnology Inc., Ltd. | Autologous BCMA-targeting CAR T cells | — | NOT YET RECRUITING | 2028-02-01 | NCT07421856 |
| Nanjing IASO Biotechnology Co., Ltd. | Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel) | — | NOT YET RECRUITING | 2029-08-31 | NCT07510100 |
| Bristol-Myers Squibb | Elotuzumab | SLAMF7-directed Immunostimulatory Antibody [EPC] | COMPLETED | 2026-02-23 | NCT02719613 |
| Bristol-Myers Squibb | bb2121 | — | COMPLETED | 2026-01-15 | NCT03601078 |
| GPCR Therapeutics, Inc. | GPC-100 | — | COMPLETED | 2025-09-30 | NCT05561751 |
| Roche | Forimtamig | — | COMPLETED | 2025-07-08 | NCT06055075 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injection | — | COMPLETED | 2025-05-20 | NCT07102706 |
| Regeneron | REGN5459 | — | COMPLETED | 2025-05-01 | NCT04083534 |
| Bristol-Myers Squibb | Pomalidomide | Thalidomide Analog [EPC] | COMPLETED | 2025-04-30 | NCT01946477 |
| Cyteir Therapeutics, Inc. | CYT-0851 | — | COMPLETED | 2024-11-30 | NCT03997968 |
| Karyopharm Therapeutics Inc | KPT-8602 | — | COMPLETED | 2024-08-31 | NCT02649790 |
| GSK | Belantamab mafodotin | — | COMPLETED | 2024-08-19 | NCT05064358 |
| Takeda | Ixazomib | — | COMPLETED | 2024-07-03 | NCT02924272 |
| Bristol-Myers Squibb | bb2121 | — | COMPLETED | 2023-12-20 | NCT03361748 |
| Janssen Scientific Affairs, LLC | Cilta-cel | — | COMPLETED | 2023-11-30 | NCT05347485 |
| Pfizer | Elranatamab | BCMA/CD3 | COMPLETED | 2023-08-06 | NCT05228470 |
| Pfizer | Elranatamab | BCMA/CD3 | COMPLETED | 2023-06-15 | NCT05014412 |
Showing 100 of 283 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDP-101 | — | RECRUITING | 2026-06-30 | NCT07529782 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0500 | — | RECRUITING | 2026-06-30 | NCT06375044 |
| Opna Bio LLC | OPN-6602 | — | RECRUITING | 2026-07 | NCT06433947 |
| iCell Gene Therapeutics | BCMA-CD19 cCAR T cells | — | RECRUITING | 2026-07 | NCT04162353 |
| OriCell Therapeutics Co., Ltd. | OriCAR-017 | — | RECRUITING | 2026-12-12 | NCT06271252 |
| Newave Pharmaceutical Inc | LP-118 | — | RECRUITING | 2026-12-31 | NCT04771572 |
| Excyte Biopharma Ltd | YKST02 | — | RECRUITING | 2026-12-31 | NCT06574568 |
| Kelonia Therapeutics, Inc. | KLN-1010 | — | RECRUITING | 2027-03 | NCT07075185 |
| Oncotherapeutics | Selinexor | Nuclear Export Inhibitor [EPC] | RECRUITING | 2027-04-01 | NCT06225310 |
| Pfizer | Elranatamab | BCMA/CD3 | RECRUITING | 2027-04-10 | NCT06215118 |
| Johnson & Johnson | JNJ-79635322 | — | RECRUITING | 2027-04-19 | NCT05652335 |
| Ichnos Sciences SA | ISB 2001 | — | RECRUITING | 2027-07 | NCT05862012 |
| Roche | Cevostamab | — | RECRUITING | 2027-07-31 | NCT05927571 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-9539 for injection | — | RECRUITING | 2027-07-31 | NCT06484777 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQB2934 injection (subcutaneous injection) | — | RECRUITING | 2027-10 | NCT07179679 |
| Johnson & Johnson | JNJ-87562761 | — | RECRUITING | 2027-11-03 | NCT06604715 |
| Johnson & Johnson | JNJ-79635322 | — | RECRUITING | 2027-11-19 | NCT06768489 |
| Caribou Biosciences, Inc. | CB-011 | — | RECRUITING | 2027-12 | NCT05722418 |
| K36 Therapeutics, Inc. | Cohort A1 & A2: KTX-1001 | — | RECRUITING | 2027-12-31 | NCT05651932 |
| Chongqing Precision Biotech Co., Ltd | Invivo CAR-T | — | RECRUITING | 2027-12-31 | NCT07239323 |
| O&D BioTech Group CO., Limited | Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D | — | RECRUITING | 2028-03-28 | NCT07369895 |
| Regeneron | Linvoseltamab | — | RECRUITING | 2028-04-11 | NCT05137054 |
| AstraZeneca | AZD0120 | — | RECRUITING | 2028-05-26 | NCT07073547 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | BMS-986393 | — | RECRUITING | 2028-08-01 | NCT06121843 |
| Roche | Cevostamab | — | RECRUITING | 2028-11-04 | NCT06934044 |
| C4 Therapeutics, Inc. | Cemsidomide | — | RECRUITING | 2028-12 | NCT07280013 |
| AbbVie | Etentamig (ABBV-383) | — | RECRUITING | 2029-08 | NCT05650632 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | BMS-986453 | — | RECRUITING | 2030-05-02 | NCT06153251 |
| AbbVie | ABBV-438 | — | RECRUITING | 2031-11 | NCT07409246 |
| AbbVie | Etentamig | — | RECRUITING | 2036-03 | NCT06896916 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQB2029 injection | — | RECRUITING | 2026-03 | NCT06700395 |
| Nanjing IASO Biotechnology Co., Ltd. | CAR-GPRC5D | — | RECRUITING | 2025-09-01 | NCT05759793 |
| Luminary Therapeutics | Autologous CAR-T cell therapy expressing the BAFF-ligand. | — | RECRUITING | 2025-07-31 | NCT05546723 |
| Oncotherapeutics | Ruxolitinib Oral Tablet [Jakafi] | — | RECRUITING | 2024-09 | NCT03110822 |
| 3D Medicines | 3D189 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT05320809 |
| Cullinan Therapeutics Inc. | CLN-619 | — | ACTIVE NOT RECRUITING | 2026-09 | NCT06381141 |
| C4 Therapeutics, Inc. | cemsidomide | — | ACTIVE NOT RECRUITING | 2026-09-30 | NCT04756726 |
| Roche | Cevostamab | — | ACTIVE NOT RECRUITING | 2026-11-18 | NCT05646836 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-4002 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT04184050 |
| AbbVie | Subcutaneous (SC) Etentamig | — | ACTIVE NOT RECRUITING | 2027-02 | NCT06223516 |
| Johnson & Johnson | Teclistamab | — | ACTIVE NOT RECRUITING | 2027-02-28 | NCT06425991 |
| Johnson & Johnson | Daratumumab | CD38-directed Cytolytic Antibody [EPC] | ACTIVE NOT RECRUITING | 2027-04-07 | NCT04108195 |
| Johnson & Johnson | Teclistamab | — | ACTIVE NOT RECRUITING | 2027-04-07 | NCT04722146 |
| Poseida Therapeutics, Inc. | P-BCMA-ALLO1 CAR-T cells | — | ACTIVE NOT RECRUITING | 2029-03 | NCT04960579 |
| Roche | Cevostamab | — | ACTIVE NOT RECRUITING | 2029-12-10 | NCT04910568 |
| Poseida Therapeutics, Inc. | Rimiducid may be administered as indicated | — | ACTIVE NOT RECRUITING | 2032-08 | NCT03741127 |
| AbbVie | Etentamig | — | ACTIVE NOT RECRUITING | 2033-09 | NCT05259839 |
| AbbVie | Etentamig | — | ACTIVE NOT RECRUITING | 2026-03 | NCT05286229 |
| Pfizer | Elranatamab | BCMA/CD3 | ACTIVE NOT RECRUITING | 2025-07-07 | NCT05675449 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-06-02 | NCT04091126 |
| Johnson & Johnson | Talquetamab | — | ACTIVE NOT RECRUITING | 2025-05-22 | NCT05338775 |
| GSK | Belantamab mafodotin | — | ACTIVE NOT RECRUITING | 2025-04-21 | NCT04398745 |
| Johnson & Johnson | Talquetamab | — | ACTIVE NOT RECRUITING | 2025-03-31 | NCT05050097 |
| Kite, A Gilead Company | anitocabtagene-autoleucel | — | ACTIVE NOT RECRUITING | 2024-10-03 | NCT04155749 |
| Hangzhou Sumgen Biotech Co., Ltd. | SG301 | — | ACTIVE NOT RECRUITING | 2024-06-30 | NCT04684108 |
| AbbVie | ABBV-453 | — | ACTIVE NOT RECRUITING | 2024-02-07 | NCT05308654 |
| Eli Lilly | LOXO-338 | — | ACTIVE NOT RECRUITING | 2023-06-14 | NCT05024045 |
| Celyad Oncology SA | CYAD-211 | — | ACTIVE NOT RECRUITING | 2022-12-21 | NCT04613557 |
| Bellicum Pharmaceuticals | BPX-501 | — | ACTIVE NOT RECRUITING | 2020-01-14 | NCT02477878 |
| Qilu Pharmaceutical Co., Ltd. | QL2109 | — | NOT YET RECRUITING | 2026-09 | NCT07400744 |
| Shanghai Henlius Biotech | HLX15-SC-Rd | — | NOT YET RECRUITING | 2027-05-25 | NCT07477587 |
| Carbiogene Therapeutics Co. Ltd. | CBG002 CAR-T Cell Suspension | — | NOT YET RECRUITING | 2027-10-25 | NCT06705725 |
| Sichuan Baili Pharmaceutical Co., Ltd. | BL-M24D1 | — | NOT YET RECRUITING | 2027-12 | NCT07255898 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-3836 administered as multiple doses. | — | NOT YET RECRUITING | 2028-04 | NCT07490613 |
| Roche | RO7851624 | — | NOT YET RECRUITING | 2030-07-01 | NCT07558915 |
| Qilu Pharmaceutical Co., Ltd. | QLS4131 Injection | — | NOT YET RECRUITING | 2026-03-31 | NCT06500507 |
| Nanjing IASO Biotechnology Co., Ltd. | Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A) | — | NOT YET RECRUITING | 2024-04 | NCT05181501 |
| Compugen Ltd | Dose escalation: COM902 monotherapy. | — | COMPLETED | 2026-04-01 | NCT04354246 |
| Takeda | TAK-079 | — | COMPLETED | 2026-03-25 | NCT03984097 |
| Roche | Forimtamig | — | COMPLETED | 2026-03-17 | NCT04557150 |
| Roche | Cevostamab | — | COMPLETED | 2026-01-07 | NCT03275103 |
| Juno Therapeutics, a Subsidiary of Celgene | CC-95266 | — | COMPLETED | 2025-12-22 | NCT04674813 |
| Arcus Biosciences, Inc. | AB308 | — | COMPLETED | 2025-08-25 | NCT04772989 |
| ORIC Pharmaceuticals | ORIC-533 | — | COMPLETED | 2025-03-03 | NCT05227144 |
| Allogene Therapeutics | ALLO-647 | — | COMPLETED | 2025-01-27 | NCT04093596 |
| Biohaven Pharmaceuticals, Inc. | — | — | COMPLETED | 2025-01-10 | NCT04634435 |
| Pfizer | Maplirpacept | — | COMPLETED | 2024-11-06 | NCT05896774 |
| Pfizer | maplirpacept (PF-07901801) | — | COMPLETED | 2024-10-02 | NCT05567887 |
| Ionis Pharmaceuticals, Inc. | ION251 | — | COMPLETED | 2024-09-30 | NCT04398485 |
| Fate Therapeutics | FT576 (Allogenic CAR NK cells with BCMA expression) | — | COMPLETED | 2024-09-20 | NCT05182073 |
| Roche | XmAb24306 | — | COMPLETED | 2024-07-10 | NCT05243342 |
| Juno Therapeutics, a Subsidiary of Celgene | CC-98633 | — | COMPLETED | 2024-07-03 | NCT04394650 |
| Baxter Healthcare Corporation | DOXIL/CAELYX | — | COMPLETED | 2024-06-21 | NCT05567601 |
| Sanofi | isatuximab SAR650984 IV | — | COMPLETED | 2024-03-27 | NCT04045795 |
| Shanghai Henlius Biotech | HLX15 | — | COMPLETED | 2024-03-16 | NCT05679258 |
| Sutro Biopharma, Inc. | STRO-001 | — | COMPLETED | 2024-02-15 | NCT03424603 |
| Pfizer | PF-06863135 monotherapy IV or SC | — | COMPLETED | 2024-01-19 | NCT03269136 |
| Ichnos Sciences SA | ISB 1342 | — | COMPLETED | 2023-12-15 | NCT03309111 |
| Bristol-Myers Squibb | CC-122 | — | COMPLETED | 2023-11-21 | NCT01421524 |
| Wuhan YZY Biopharma Co., Ltd. | Y150 | — | COMPLETED | 2023-10-23 | NCT05011097 |
| Bristol-Myers Squibb | bb2121 | — | COMPLETED | 2023-06-07 | NCT04196491 |
| Mundipharma Research Limited | Tinostamustine | — | COMPLETED | 2023-05-30 | NCT02576496 |
| Nektar Therapeutics | NKTR-255 | — | COMPLETED | 2023-04-24 | NCT04136756 |
| GSK | Belantamab mafodotin | — | COMPLETED | 2023-04-06 | NCT03828292 |
| CASI Pharmaceuticals, Inc. | CID-103 | — | COMPLETED | 2023-01-19 | NCT04758767 |
| MiNK Therapeutics | agenT-797 | — | COMPLETED | 2023-01-13 | NCT04754100 |
| 2seventy bio | bb21217 | — | COMPLETED | 2022-12-02 | NCT03274219 |
| Janssen Pharmaceutical K.K. | Talquetamab | — | COMPLETED | 2022-10-14 | NCT04773522 |
| Amgen | Immediate Release (IR) Formulation | — | COMPLETED | 2022-10-06 | NCT02939183 |
| Pfizer | Elranatamab (PF-06863135) | — | COMPLETED | 2022-05-27 | NCT04798586 |
Novel Drugs by Company (New molecular entities)
+7 more companies
Reformulations (14 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
IVRA
Apotex
T3 2023
HEPZATO
DELCATH SYSTEMS INC
T4 2023
FRINDOVYX
AVYXA HOLDINGS
T5 2023
DARZALEX FASPRO
Johnson & Johnson
T3/4 2020
HEMADY
DEXCEL
T4/5 2019
EVOMELA
ACROTECH BIOPHARMA
EFFICACY 2016
POMALYST
Bristol-Myers Squibb
T1 2013
KYPROLIS
ONYX PHARMS AMGEN
T1 2012
MOZOBIL
Sanofi
T1 2008
REVLIMID
Bristol-Myers Squibb
T1 2005
VELCADE
Takeda
T1 2003
THALOMID
Bristol-Myers Squibb
T1 1998
BICNU
AVET LIFESCIENCES
T1 1977
CYTOXAN
Baxter
T1 1959
Drug Targets
Generic Drugs (6 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs